AstraZeneca ramping up virtual R&D model

AstraZeneca's (AZN) virtual iMed Oncology division signs an R&D deal with Korea Health Industry to identify early stage projects suitable for funding. The twelve most promising proposals will be chosen for development.

The company formed iMed in 2012 as it eliminated 2,200 R&D jobs in an effort to cut costs and increase efficiency. Replacing the large centrally-located bureaucratic structure is a small in-house staff that interacts remotely with collaborators and contractors around the world.

iMed's initial success in neuroscience prompted the move into oncology.

From other sites
Comments (1)
  • Gus999
    , contributor
    Comment (1) | Send Message
    I think is the right time to invest in AZN now that still cheap. Cosindering that next year the pipeline will grow exponentially so will the dividends...
    7 Mar 2014, 04:34 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs